Results from an Open-Label Phase 2a Study of Cerdulatinib, a Dual Spleen Tyrosine Kinase/janus Kinase Inhibitor, in Relapsed/refractory Peripheral T-cell Lymphoma
LEUKEMIA & LYMPHOMA（2025）
关键词
Peripheral T-cell lymphoma,dual spleen tyrosine kinase/janus kinase inhibitor,phase-2 study,relapsed/refractory
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要